175 results
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
3 Dec 19
Departure of Directors or Certain Officers
6:55am
Exhibit 10.1
EyeGate Pharmaceuticals, Inc.
Amended and Restated Change in Control Severance Plan
1. Purpose of Plan.The Company hereby adopts … on November 27, 2017 (the “Plan”). The purpose of the Plan is to ensure that employees of EyeGate Pharmaceuticals, Inc. (the “Company”) and its
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
license to Licensed Technology for the purpose of Developing, Registering, Manufacturing and Commercializing the Licensed Product in the Territory … Product in human the purpose of which is preliminary determination of safety of such Licensed Product in healthy individuals or patients that would satisfy
8-K
EX-3.1
9smb84 pl9iwrig
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am
DRS/A
EX-10.2
22jzk88q
8 Jul 14
Draft registration statement (amended)
12:00am
8-K
EX-10.1
fx7cv36cm3 kyf
1 Feb 21
Departure of Directors or Certain Officers
6:55am
8-K
EX-10.2
7ypj hoj7xrpxxqmtz
30 Sep 19
EyeGate Enters Into Agreement for $1.9 Million Private Placement
6:55am
DRS/A
EX-10.3
j7dpc mcnur
8 Jul 14
Draft registration statement (amended)
12:00am
8-K
EX-10.2
6c2b7dg2y1nmhr5rjys
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm
8-K
EX-4.2
rvzuj3
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-10.1
27dl145kh
21 Nov 22
Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million
7:00am
8-K
EX-10.2
p2i25 0kvk3nitx
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
8-K
EX-10.1
7wyspa
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am
S-8
8ahe h1vtlyl8g4nl
20 Feb 15
Registration of securities for employees
12:00am